Garuda - Garba Rujukan Digital

p-Index From 2019 - 2024

0.882

P-Index

This Author published in this journals

All Journal Farmaka Indonesian Journal of Pharmaceutical Science and Technology Jurnal Farmasi Klinik Indonesia Pharmacology and Clinical Pharmacy Research

AJENG DIANTINI

Unknown Affiliation

Author-ID : 2696573

Biochemistry, Genetics & Molecular Biology Chemistry Computer Science & IT Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Public Health

Published : 8 Documents Claim Missing Document

Claim Missing Document

Articles

Title

Efficacy and Side Effects of Deferasirox and Deferiprone for Thalasemia Major in Children Asti Y. Rindarwati; Ajeng Diantini; Keri Lestari
Pharmacology and Clinical Pharmacy Research Vol 1, No 3
Publisher : Universitas Padjadjaran, Indonesia

Thalassemia major (TM) is an inherited disease caused by defective or absent of hemoglobin chain synthesis. Regular chelation therapy is necessary to reduce excess iron in several organs of TM patients. The most commonly used chelating agents are deferasirox and deferiprone. However, information regarding their effectiveness and side effects in Indonesian children population with TM were limited. This study was conducted to assess the effectiveness and side effects of deferasirox and deferiprone in pediatric patients with TM. This was an observational study with prospective analysis which was conducted during April-August 2015. We included pediatric patients with TM who visited a hospital in Bandung, Indonesia, using consecutive sampling method. Thirty two subjects were divided into two groups, i.e., deferasirox and deferiprone group. Review of medical records and interview were performed for each participants. Effectiveness was defined as reduction in ferritin level. Side effects were assessed using Naranjo scale. Data were analyzed using Mann-Whitney test, Wiloxon test and Chi square test. P value < 0.05 defined statistical significance. We found that deferasirox was more effective than deferiprone for the treatment of TM in pediatric patiens, with less side effects. The use of deferasirox as iron chelating agent is recommended for patients with TM.Keywords: deferasirox, deferiprone, ferritin, thalassemia major

Effectiveness of Erythropoietin in Hypertensive Hemodialysis Patients Susannia Ibrahim; Ajeng Diantini; Budhi Prihartanto; Rudi Supriyadi
Pharmacology and Clinical Pharmacy Research Vol 2, No 2
Publisher : Universitas Padjadjaran, Indonesia

Chronic renal failure (CRF) is one the most prevalent health problems among the elderly. Onthe fifth stage of CRF, the patient becomes eligible to hemodialysis. CRF-induced anemiais commonly treated with Erythropoietin (Epo). Information regarding the effectiveness ofEpo in hypertensive hemodialysis patients was limited. Therefore, this study was conductedto evaluate the effectiveness of Epo in hypertensive hemodialysis patients. This study usedan observational case-control analytic method. Data were retrieved from the medical recordsof hemodialysis patients during March-May 2014. A total of 54 participants were included.The increase of haemoglobin (Hb) in controlled hypertension was 0.6257 g/dl, while the inuncontrolled hypertension group, there was a decrease in Hb (-0.1590 g/dl). The use of Epowas more effective in hemodialysis patients with controlled hypertension.Keywords: chronic kidney disease, erythropoietin, hypertension

Co-Authors ALIA RESTI AZURA Angga Geganaputra Asti Y. Rindarwati Budhi Prihartanto Cynthia R. Sartika Fitri N. Ramadhani Ida Musfiroh Jutti Levita Keri Lestari Melisa I. Barliana Miswar Fattah Muchtaridi Muchtaridi Muhammad F. Effendi Nadiya N. Afifah Rudi Supriyadi Ruri Intania Shelly Iskandar Sofa D. Alfian Sra R. Anggraeni Susannia Ibrahim Yanni Dirgantara Yasmiwar Susilawati

Title Search

Found 2 Documents Search Journal : Pharmacology and Clinical Pharmacy Research

Abstract

Abstract

Title

Found 2 Documents
Search
Journal : Pharmacology and Clinical Pharmacy Research